Pages

November 05, 2024

Phibro acquires Zoetis' medicated feed additive business

November 5, 2024 - Phibro Animal Health has completed the acquisition of the medicated feed additive product portfolio and certain water-soluble products from Zoetis. The company says that this acquisition marks a significant step in furthering Phibro's purpose to optimise global animal health and nutrition for better lives and a more sustainable world.

The acquisition includes a product portfolio with more than 37 product lines sold across approximately 80 countries, six manufacturing sites in the US, Italy and China, and a team of more than 300 employees who primarily support the manufacturing and distribution activities of the business.

"Adding this new lineup of medicated feed additives and water-soluble products across cattle, swine and poultry will complement and expand Phibro's species and product portfolios, helping customers meet the highest standards of animal care, prevent disease and enhance nutrition around the world," said Jack C Bendheim, Chairman, President and CEO of Phibro Animal Health. "These products fit Phibro's core competencies and capabilities while complementing our current lineup of vaccines, nutritional specialties and mineral nutrition."

"This is a win-win-win," said Larry Miller, Phibro's Chief Operating Officer. "For our customers, it broadens the solution options and expertise that Phibro brings to support animal health globally; for consumers, it helps continue to ensure that food is produced safely and sustainably; and for our investors, it expands and diversifies our revenue base, ultimately generating funding to support future investment in additional fast-growing animal health product categories."

The portfolio is expected to boost Phibro’s profitability and EBITDA margin and be accretive to its Adjusted Earnings Per Share.

The Global Miller
This blog is maintained by The Global Miller staff and is supported by the magazine Milling and Grain
which is published by Perendale Publishers Limited.

No comments:

Post a Comment